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17b-Hydroxysteroid dehydrogenases involved in local oestrogen
synthesis have prognostic significance in breast cancer
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The 17b-hydroxysteroid dehydrogenase (17HSD) enzymes are involved in the local regulation of sex steroids. The 17HSD type 1
enzyme catalyses the interconversion of the weak oestrone (E1) to the more potent oestradiol (E2), whereas 17HSD type 2
catalyses the oxidation of E2 to E1. The aim of this study was to correlate the expression of these enzymes in the tumour with the
recurrence-free survival of tamoxifen-treated breast cancer patients. We used real-time reverse transcriptase PCR to investigate the
mRNA expression of 17HSD types 1 and 2 in tumour samples from 230 postmenopausal patients. For the patients with oestrogen
receptor (ER)-positive breast cancer, we found a statistically significant positive correlation between recurrence-free survival and
expression of 17HSD type 2 (P¼0.026). We examined the ratio of 17HSD types 2 and 1, and ER-positive patients with low ratios
showed a significantly higher rate of recurrence than those with higher ratios (P¼0.0047). ER positive patients with high expression
levels of 17HSD type 1 had a significantly higher risk for late relapse (P¼0.0051). The expression of 17HSD types 1 and 2 in breast
cancer differs from the expression of these enzymes in normal mammary gland, and this study indicates that the expression has
prognostic significance in breast cancer.
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Oestrogens play an important role in the development of
hormone-dependent breast cancer. In premenopausal women,
the majority of oestrogen is produced in the ovaries. In
postmenopausal women, local oestrogens in breast carcinoma
tissue originate through two main pathways, one involving
aromatase, which converts androgens to oestrogens, and the other
utilising steroid sulphatase, which converts oestrone sulphate into
oestrone. 17b-Hydroxysteroid dehydrogenase (17HSD) activity is
finally needed for the oestradiol/ oestrone regulation.
The 17HSD type 1 enzyme uses NADPH as a cofactor and
catalyses the interconversion of the weak oestrogen, oestrone (E1),
to the biologically more potent oestradiol (E2). 17b-Hydroxyster-
oid dehydrogenase type 2 uses NADþ as a cofactor and catalyses
the oxidation of testosterone and oestradiol to form androsten-
dione and oestrone, respectively (Miettinen et al, 1996; Vihko et al,
2001). Previous studies have reported the presence of multiple
17HSD isoenzymes in humans, including type 3 and 4 (Speirs et al,
1998, 1999; Peltoketo et al, 1999), although types 1 and 2 seem to
be the principal enzymes involved in reductive and oxidative
activity in breast cancer, respectively (Miettinen et al, 1999).
Moreover, previous studies have suggested that oestradiol can be
produced in the same organ where it exerts its biological response.
This is in agreement with the fact that breast cancer tissue
possesses all the enzymes necessary for the bioformation of
oestradiol (Yue et al, 1998; Purohit et al, 2002).
A few immunohistochemical studies of 17HSD type 1 in human
breast cancer have been reported, suggesting that 17HSD type 1
may play an important role in the in situ regulation of oestradiol
production in hormone-dependent breast carcinomas (Poutanen
et al, 1992; Sasano et al, 1996; Suzuki et al, 2000). In a previous
study, we found that the expression of both 17HSD types 1 and 2
differ in the tumours of patients with and without late relapse in
the disease (Gunnarsson et al, 2001).
Oestrogen receptor (ER)-positive breast cancer is usually treated
with tamoxifen, and long-term adjuvant tamoxifen is beneficial
compared with treatment of shorter duration (Swedish Breast
Cancer Cooperative Group, 1996). We hypothesised that the
expression levels of 17HSD types 1 and 2, by affecting
intratumoural oestradiol levels, might influence the response to
endocrine treatment of breast cancer. The purpose of this study
was to analyse the prognostic significance of 17HSD types 1 and 2
expression in a series of postmenopausal patients treated with
adjuvant tamoxifen.
MATERIAL AND METHODS
We analysed frozen tissue from excised primary breast tumours of
230 women treated in the health-care region of southeast Sweden
between 1985 and 1991. The patients were participants in a
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srandomised multicentric trial where 2 and 5 years of adjuvant
postoperative tamoxifen treatment was compared for postmeno-
pausal patients less than 75 years of age (Swedish Breast Cancer
Cooperative group). The daily dose of tamoxifen was 40mg. All
patients had primary breast cancer, stage II (UICC), without
distant metastasis at the time of diagnosis. The median period of
follow-up was 13.9 years. Primary surgery consisted of either
modified radical mastectomy or breast-conserving surgery com-
bined with axillary lymph node dissection. Radiotherapy (50Gy) to
the breast was offered to all patients treated with breast-conserving
surgery. Lymph node-positive patients were treated with radiation
directed to the breast/chest wall and regional lymph nodes. After
surgery, the tumour samples were stored in a freezer ( 701C) until
RNA extraction was performed. Oestrogen receptor and proges-
terone receptor (PgR) content was measured in clinical routine
practice with isoelectric focusing before 1988 and thereafter with
enzyme immunoassays (EIA) (Abbott Laboratories, Chicago, IL,
USA). Samples with concentrations X0.1fmolmg
 1 DNA (or
X0.3fmolmg
 1 DNA with EIA) were classified as positive. The
present material is a subset of the patients in the region who
participated in the trial, and includes the patients for whom frozen
tumour samples were available after hormone receptor analysis.
The characteristics of the tumours were similar to those in the
complete series as regards a positive lymph node status (71 vs
74%), tumour size larger than 20mm (69 vs 60%) and a positive ER
status (78 vs 76%). The study was approved by the regional ethics
committee at Linko ¨ping University.
RNA extraction
Frozen breast tumour tissue (30mg) was homogenised in a
microdismembrator (B Braun, Melsungen, Germany), and total
RNA was extracted with the SV total RNA isolation system
(Promega, Madison, WI, USA). The purified RNA was stored at
 701C, and the RNA content was determined by spectrophoto-
metry. We also examined the expression of 17HSD types 1 and 2 in
normal mammary gland. Total RNA from a pool of human breast
tissue samples from 3 women (age 46–54 years) was purchased
from ADH diagnostics (Life Technologies, Inc.).
cDNA synthesis
Total RNA (500ng) was reverse-transcribed in a final volume of
20ml, using Gibko BRL kit (Life Technologies, Inc., Stockholm,
Sweden) with the following concentrations: 1 PCR buffer, 5mM
MgCl2, 0.5mM deoxynucleotide triphosphates, 2.5mM random
hexamers, 10mM DTT, and 0.5ml of Superscript reverse tran-
scriptase (Life Technologies, Inc.) The thermal conditions used
were as follows: 201C for 10min, 421C for 50min, 991C for 5min,
and after that 51C. The samples were stored at 41C as the real-time
PCR analysis was performed during the same day.
Primers and probes
We used the computer software Primer Express (PE Applied
Biosystems, Foster City, CA, USA) to design primers and probes
that recognised human 17b-HSD types 1 and 2 cDNA sequences.
We conducted Blast searches (GenBank) to confirm the specificity
of nucleotide sequences chosen for the primers and probes and the
absence of DNA polymorphism. To avoid detection of contam-
inating genomic DNA, the probe was placed in the junction
between two exons. The primer and probe sequences were; 17HSD
type 1: forward primer: 50-TAT GCG AGA GTC TGG CGG TT-30,
reverse primer: 50-TGC ACT GGG CCG CAC T-30, probe: 50-CGA
TCA GGC TCA AGT GGA CCC CAA-30; 17HSD type 2: forward
primer: 50-TTA CCT GTG GAT CAG AAG GCA GT-30, reverse
primer: 50-TTG CAC AAA GCA TGG CCA-30, probe: 50-CCC GCA
ATC ACC ACC TGT CAC CA-30. Both primers and probes were
purchased from PE Applied Biosystems, as were the primers and
probes for b-actin, which was used as endogenous control gene.
Real-time PCR
The reactions were performed in the ABI Prism 7700 Sequence
Detection System (PE Applied Biosystems). The design of the
TaqMan probes, combined with the 50–30nuclease activity of
AmpliTaq Gold DNA polymerase (PE Applied Biosystems), allows
the direct detection of the PCR product by the release of a
fluorescent reporter during the PCR.
PCR conditions
cDNA (3ml) was added to the reaction mixture, which had a total
volume of 25ml. With the TaqMan PCR core reagent kit (PE
Applied Biosystems) the concentrations used were as follows:
1 TaqMan buffer A, 5.0mM MgCl2, 0.1mM deoxynucleotide
triphosphates, 0.1mM each of forward and reversed primers, 0.1mM
probe, and 0.025 unitsml
 1 AmpliTaq Gold DNA polymerase. The
thermal conditions used were 951C for 10min, 951C for 15s and
601C for 1min. Steps two and three were repeated for 40 cycles.
When we used the synthesised cDNA for each tumour, the 17b-
HSD types 1 and 2 and b-actin specific sequences were amplified
independently in separate reaction wells in triplicate. On the same
plate, we included samples for standard curves for the target genes.
Standard curve method
A relative kinetic method was applied, using a standard curve,
which was constructed with four-fold serial dilutions of cDNA
from normal breast tissue. Standard curves were produced for the
three target genes after each run. The target messages in unknown
samples were quantified, using the standard curves, to determine a
relative measure of the starting amount. The measures were
normalised, which means that the level of 1 represents the
expression level in normal mammary tissue.
Statistical analysis
The relationships between grouped variables were analysed with
the w
2 test. Survival curves were produced according to the life-
table method described by Kaplan and Meier. Differences in
recurrence-free survival were estimated with the log-rank test.
Multivariate analysis of recurrence and mortality rates was
performed with Cox proportional hazard regression. All the
procedures are comprised in the statistical package STATISTICA
6.0 (StatSoft Scandinavia AB, Sweden). The criterion for statistical
significance was Po0.05.
RESULTS
The 17HSD type 1 enzyme was detected in all of the 230 tumours
analysed with a mean value of 2.3. The tenth and the ninetieth
percentile for 17b-HSD type 1 were 0.1 and 8.2, respectively. To
discriminate between low/intermediate and high expression of
17HSD type 1, the material was divided into two groups according
to the mean level; lower (o2.3), and higher (42.3). 17b-
Hydroxysteroid dehydrogenase type 2 mRNA was detected in
69% of the tumours. The tenth and ninetieth percentile for 17HSD
type 2 were 0.0 and 0.92, respectively. The mean expression level
for 17HSD type 2 was 0.28. To categorise the patients into two
groups the mean value was used as cutoff. Since 17HSD types 1 and
2 cooperate to regulate the levels of E2 and E1, we also determined
the ratio between these enzymes in each tumour. The majority
showed low ratios as compared to normal. Using the upper tertile
as cutoff level, we divided the material into groups with higher
(40.2) or lower (o0.2) ratios. The expression of 17HSD types 1
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sand 2 were not significantly associated with other tumour
characteristics, such as lymph node status, tumour size, ER status
or PgR status (Table 1).
Prognostic value of 17HSD
Oestrogen receptor-positive patients whose tumour had a high
ratio (17HSD2/17HSD1 40.2) showed a significantly better
prognosis than patients with low ratios (P¼0.0047), whereas no
association was found among ER negative patients (P¼0.34)
(Figure 1). This stayed true in multivariate analysis, with regard to
recurrence-free survival as well as breast cancer-specific survival
(Table 2). A similar result was found for 17HSD type 2 alone.
Among ER-positive patients, those with low expression of type 2
had a significantly higher recurrence rate compared with patients
who expressed normal levels (P¼0.026) (Figure 2). This difference
could not be seen among ER-negative patients (P¼0.62). The
prognostic significance of type 2 hold true in multivariate analysis
(P¼0.042). There was no significant association between 17HSD
type 1 and recurrence-free survival if the entire follow-up period
was considered (Figure 3A). However, for ER positive patients still
recurrence-free after 5 years, high levels of 17HSD type 1 was
associated with a significantly higher rate of late relapse in the
disease (P¼0.0051) (Figure 3B).
Expression of 17HSD and benefit of 5 vs 2 years tamoxifen
treatment
Oestrogen receptor-positive patients with low 17HSD2/17HSD1
ratios tended to have the advantage of 5 instead of 2 years
tamoxifen treatment (5 vs 2 years recurrence rate ratio, RR¼0.56,
95% CI, 0.29–1.06, P¼0.072). This difference could not be seen
among patients with high ratios (RR¼0.92 (0.28–3.0), P¼0.90).
The same pattern was observed for 17HSD type 2 alone, that is, ER-
positive patients with low expression benefited from prolonged
Table 1 17b-Hydroxysteroid dehydrogenase (17HSD) types 1 and 2
expression and the 17HSD2/17HSD1 ratio in relation to tumour
characteristics and tamoxifen treatment
17HSD1 17HSD2 HSD2/HSD1
o2.3 42.3 o0.28 40.28 o0.2 40.2
n¼171 n¼59 n¼175 n¼55 n¼154 n¼76
Lymphnode status/
tumour size (mm)
N , 420 48 (75) 16 (25) 47 (73) 17 (27) 39 (61) 25 (39)
N+, p20 50 (72) 19 (28) 55 (80) 14 (20) 53 (77) 16 (23)
N+, o20 68 (77) 20 (23) 66 (75) 22 (25) 54 (61) 34 (39)
ER status
ER  36 (71) 15 (29) 42 (82) 9 (18) 36 (71) 15 (29)
ER+ 135 (75) 44 (25) 133 (74) 46 (26) 118 (66) 61 (34)
PgR status
PR  67 (73) 25 (27) 73 (79) 19 (21) 65 (71) 27 (29)
PR+ 104 (75) 34 (25) 102 (74) 36 (26) 89 (64) 49 (36)
Tamoxifen
TAM 2 years 74 (64) 41 (36) 81 (70) 34 (30) 76 (66) 39 (34)
TAM 5 years 97 (84) 18 (16) 94 (82) 21 (18) 78 (68) 37 (32)
ER  −
ER  −
HSD2/HSD1 > 0.2
P = 0.34 
HSD2/HSD1 < 0.2
ER+
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Figure 1 Recurrence-free survival (A, B) and breast cancer survival (C, D) in relation to the ratio of 17b-hydroxysteroid dehydrogenase (17HSD) type 2
and type 1 mRNA expression (17HSD2/17HSD1). (A, C) oestrogen receptor-positive (ERþ) patients (n¼179) and (B, D) ER negative patients (n¼51).
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streatment, whereas those showing higher type 2 levels appeared to
have similar recurrence-free survival with 2 and 5 years of
treatment (5 vs 2 years, RR¼0.60 (95% CI, 0.35–1.04) and
RR¼1.01 (0.28–3.6), respectively). Oestrogen receptor-positive
patients with lower levels of 17HSD type 1 showed a 40% reduced
risk of recurrence with prolonged treatment (RR¼0.60 (0.33–
1.09)), whereas a benefit from prolonged treatment was not evident
for those with increased type 1 (RR¼1.33 (0.52–3.4)). However,
the difference between the groups was not statistically significant.
DISCUSSION
For ER positive patients in this study, the 17HSD2/17HSD1 ratio
had a prognostic significance. A higher 17HSD2/17HSD1 ratio
gives an increased oxidative activity (E2-E1), and in the present
study, this was associated with a good prognosis. In contrast, a low
ratio leads to increased reductive activity (E1-E2). Irrespective of
E1 production, as a result of aromatase or steroid sulphatase
activity, 17HSD types 1 and 2 are responsible for the balance of E1
and E2. It has previously been shown that in normal breast tissue
the oxidative pathway (E2-E1) dominates, whereas in malignant
breast tumours the reductive pathway (E1-E2) is dominant
(Speirs et al, 1998). These results suggest that intratumoral
regulation of oestradiol levels is of importance.
Other enzymes involved in oestrogen synthesis may have
prognostic significance, and Utsumi and colleagues (1999)
suggested steroid sulphatase as a useful marker for identification
of high-risk breast cancer patients. Miyoshi et al (2001) observed
that intratumoral E2 levels are not significantly different between
premenopausal and postmenopausal patients and the authors
suggested that upregulation of 17HSD type 1 is important in the
maintenance of high intratumoral E2 levels especially in post-
menopausal patients. In a more recent study, Miyoshi et al (2003)
demonstrated that the intratumoral sulphatase mRNA levels, but
not the aromatase and 17b-HSD1 mRNA levels, have prognostic
Table 2 Multivariate analysis (Cox) of recurrence rate ratio and breast
cancer mortality rate ratio for oestrogen receptor (ER)-positive patients in
relation to 17b-hydroxysteroid dehydrogenase (17HSD) types 1 and 2 and
other variables
Recurrence Breast cancer mortality
RR (95% CI) Significance RR (95% CI) Significance
HSD2/HSD1
p0.2 1.0 1.0
40.2 0.43 (0.23–0.80) P¼0.0083 0.43 (0.22–0.85) P¼0.015
Nodal status
N  1.0 1.0
N+ 2.2 (1.09–4.3) P¼0.027 2.6 (1.2–5.5) P¼0.012
Tumour size (mm)
p20 1.0 1.0
420 1.5 (0.83–2.7) P¼0.18 2.1 (1.08–4.2) P¼0.030
PgR status
PgR  1.0 1.0
PgR+ 0.72 (0.42–1.2) P¼0.24 0.73 (0.41–1.3) P¼0.30
Tamoxifen
2 years 1.0 1.0
5 years 0.75 (0.45–1.25) P¼0.27 0.99 (0.57–1.7) P¼0.98
P = 0.026 
HSD type 2 > 0.28
HSD type 2 < 0.28
ER+
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Figure 2 Recurrence-free survival for oestrogen receptor-positive
patients with decreased (o0.28) and normal (40.28) expression of
17b-hydroxysteroid dehydrogenase (HSD) type 2 mRNA (n¼133 and
n¼46, respectively).
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Figure 3 Recurrence-free survival for oestrogen receptor-positive
patients with low/normal (o2.3) and increased (42.3) expression of
17b-hydroxysteroid dehydrogenase (HSD) type 1 mRNA (n¼135 and
n¼44, respectively). The entire follow-up period is shown in (A). Patients
still recurrence-free after 5 years were analysed for later events and their
outcome is shown in (B).
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svalue in ER-positive breast cancer patients. In the same study,
patients with high levels of 17HSD type 1 tended to have a worse
prognosis than those with low levels.
The gene encoding 17HSD type 1 is located at 17q12–21, a
region that often is rearranged in breast cancer (Plummer et al,
1997, Kauraniemi et al, 2001). In a recent study, we found
amplification of the gene encoding 17HSD type 1 in 14.5% of the
breast tumours (Gunnarsson et al, 2003).
In the present study, we found that a high expression of 17HSD
type 1 predicted late recurrence among ER-positive patients and
apparently decreased benefit from prolonged tamoxifen treatment.
This could indicate that tamoxifen does not completely block the
action of E2 in some patients due to high levels of E2. Acquired
tamoxifen resistance is believed to arise due to increased
phosphorylation of the ER by growth factor signalling or due to
increased expression of coactivators (Nicholson et al, 2004, Schiff
et al, 2004). This means that tamoxifen acts as an agonist after long
duration of treatment in some patients, and the question is how
the resistant tumour cells will respond to high E2 levels after the
completion of tamoxifen treatment. It has previously been shown
that tamoxifen treatment for longer periods than 5 years is not
preferable (Fisher et al, 2001). A recent study pointed out
aromatase inhibitor as significantly more efficient than placebo
among postmenopausal women after 5 years tamoxifen treatment
(Goss et al, 2003). Some ER-positive patients with metastatic
disease who have failed on tamoxifen treatment still show response
to aromatase inhibitors (Dowsett, 1997). In particular, for patients
with high intratumoral E2 levels the switch to aromatase inhibitor
after some period of tamoxifen treatment could be favourable.
Suzuki et al (2000) observed that 17HSD type 1 was
immunolocalised in carcinoma cells in a majority of invasive
ductal carcinomas, while 17HSD type 2 was not detected in any of
the cases. The authors suggested that type 1 is the enzyme of
interest in breast cancer. In a previous case/control study, we
found that a low or undetectable level of type 2 as well as a high
expression of type 1 was associated with a worse prognosis in
breast cancer (Gunnarsson et al, 2001). The results in the present
study are in line with the previous study; however, the present
series is larger and not selected as in the case/control study.
Among ER positive patients in the present study there was a
significant difference in prognosis in relation to 17HSD type 2.
Patients who had a low or undetectable level of type 2 had a
significantly higher risk of recurrence. These results stayed true in
multivariate analysis including other prognostic factors. The loss
of 17HSD type 2 expression could result in a significant increase of
the more biologically active E2. It has been shown in colon cancer
that loss of type 2 is an early event in cancer development, and the
authors suggested that type 2 protects the colonic mucosa from E2
(English et al, 2001). In a more recent study, Oduwole et al suggest
that low expression of 17HSD type 2 in colon cancer is an
independent marker of favourable prognosis in females. The
female patients with high expression of type 2 had a poor
prognosis and often tumours with a mucinous component
(Oduwole et al, 2003).
The gene encoding 17HSD type 2 is located at 16q24 and loss of
heterozygosity (LOH) at this site is a frequent and early event in
breast cancer (Cleton-Jansen et al, 2001). Moreover, in prostate
cancer, LOH at 16q is common, and Elo et al (1997) discussed
whether activity of 17HSD type 2 protects prostatic epithelial cells
from excessive androgen action and reduces the proliferative
pressure on prostatic cells. Significantly decreased mRNA expres-
sion of 17HSD type 2 in prostate cancer as compared to
normal prostate tissue has also been reported (Koh et al, 2002).
In the future, it would be of interest to see if the high frequency of
LOH at 16q24 in breast cancer includes the gene coding for 17HSD
type 2.
We found that 17HSD type 2 was expressed in the normal
mammary gland, whereas the expression levels were low or
undetectable in a majority of ER positive breast neoplasms. We
also found a favourable prognosis among patients with ER positive
tumours that expressed higher mRNA levels of the enzyme. As the
loss of 17HSD type 2 activity results in an increased reductive
activity (E1-E2), this might be an important mechanism in the
pathogenesis of ER-positive breast cancer. Previous studies have
shown most interest in 17HSD type 1. This study indicates that
17HSD type 2 and the 17HSD2/17HSD1 ratio may be even more
important, which motivates further investigations.
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